The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.
GlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with endometrial cancer that has a specific genetic mutation. In an update ...
Hosted on MSN8mon
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer PatientsDostarlimab—known generically as Jemperli—was developed by GSK in partnership with the biotech firm AnaptysBio in 2014, as the company expanded into cancer drug sales. The drug was approved by ...
Hosted on MSN11mon
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer StudyGSK plc (NYSE: GSK) announced headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab ...
Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback